Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a TurnaroundZacks Investment Research • 01/21/25
After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)Zacks Investment Research • 01/20/25
Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 WeeksZacks Investment Research • 01/15/25
Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 01/14/25
Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a BetZacks Investment Research • 12/04/24
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to TradeZacks Investment Research • 11/18/24
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 11/14/24
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel DiseaseBusiness Wire • 11/04/24
Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect?Zacks Investment Research • 11/01/24
Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/29/24
Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should KnowZacks Investment Research • 10/16/24
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel DiseasesBusiness Wire • 10/10/24
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness Wire • 09/12/24
Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?Zacks Investment Research • 09/12/24
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology ProgramsBusiness Wire • 09/09/24
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024Business Wire • 09/06/24